Document is current

Article History

Received: 2 July 2021

Accepted: 26 November 2021

First Online: 8 January 2022

Declarations

:

: Kohei Shitara received honoraria from Novartis, AbbVie Inc, and Yakult; research funding from Dainippon Sumitomo Pharma, Daiichi Sankyo, Taiho Pharmaceutical, Chugai Pharma, Merck Pharmaceutical, Medi Science, and Eisai; and fees as an advisor to Novartis, AbbVie Inc, Daiichi Sankyo, Taiho Pharmaceutical, Merck Pharmaceutical, GlaxoSmithKline, Amgen, and Boehringer Ingelheim. Toshihiko Doi received personal fees from Lilly, MSD, Daiichi Sankyo, Amgen, Sumitomo Dainippon, Taiho, Novartis, Boehringer Ingelheim, Takeda, Chugai Pharma, Bristol-Myers Squibb, AbbVie, Bayer, Rakuten Medical, Ono Pharmaceutical, Astellas Pharma, and Oncolys BioPharma; and grants from Lilly, MSD, Daiichi Sankyo, Sumitomo Dainippon, Taiho, Novartis, Merck Serono, Janssen, Boehringer Ingelheim, Pfizer, Bristol-Myers Squibb, AbbVie, Quintiles, and Eisai. Hisashi Hosaka received grants from Taiho Pharmaceutical Co., Ltd. Peter Thuss-Patience served on advisory boards and received personal fees from Servier, Roche, BMS, MSD, Lilly, Merck Serono, Pfizer, and AstraZeneca. Armando Santoro served on advisory boards for BMS, Servier, Gilead, Pfizer, Eisai, Bayer, and MSD; as a consultant for ArQule and Sanofi; and as a speaker for Takeda, BMS, Roche, AbbVie, Amgen, Celgene, Servier, Gilead, AstraZeneca, Pfizer, ArQule, Eli Lilly, Sandoz, Eisai, Novartis, Bayer, and MSD. Federico Longo received fees as an advisor, non-financial support, and travel for meetings from Servier, Lilly, Roche, BMS, MSD, Amgen, and Merck; and institutional grant funding from MSD. Aziz Zaanan served on advisory boards and received personal fees from Amgen, Merck, Roche, Sanofi, Servier, MSD, Pierre Fabre, Havas Life, Alira Health, and Zymeworks. Maria Alsina received fees as an advisor to MSD, BMS, Servier, and Lilly. Lukas Makris provided statistical design and analysis to Taiho Oncology, Inc. (during and outside the conduct of the study); and has provided statistical design and analysis services to other pharmaceutical companies and Independent Data Monitoring Committees. Karim A Benhadji is an employee of Taiho Oncology, Inc. and a former employee and stockholder of Eli Lilly. David H. Ilson served on advisory boards and received personal fees from Taiho (during conduct of the study), Roche, Merck, Bristol Myers Squibb, and Astellas. Ozgur Ozyilkan, Irfan Cicin, David Park, Carles Pericay, and Mustafa Özgüroğlu declare that they have no conflict of interest.